Home » PRECISIONMED, INC. AND DX INNOVATIONS, INC. ANNOUNCE PATENT FILING
PRECISIONMED, INC. AND DX INNOVATIONS, INC. ANNOUNCE PATENT FILING
PrecisionMed, Inc. and Dx INNOVATIONS, Inc. are pleased to announce the results of a collaborative effort that enabled novel diagnostic procedures based on extracellular nucleic acids identified in cerebrospinal fluid. Dx INNOVATIONS' technology detected extracellular free circulating
nucleic acids in cerebrospinal fluid that is most likely the product of programmed
cell death (apoptosis), a natural process that allows the body to remodel or recycle
tissue.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May